Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06427330 | Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia | unknown | Phase 2 | 21 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT04778579 | Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy(CART19-BE-02) | unknown | Phase 2 | 50 | Sara V. LatorreOTHER | 1 |
| Jun 26, 2024 |
| clinicaltrials |
| NCT02061800 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | unknown | Phase 1 / Phase 2 | 14 | Diane GeorgeOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03275493 | CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia | unknown | Phase 1 / Phase 2 | 40 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT06078306 | CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04731974 | Acute Concussion and Melatonin | unknown | Phase 2 | 254 | Children's National Research InstituteOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06141304 | Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT | unknown | Phase 2 | 28 | The First Hospital of Jilin UniversityOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06087419 | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | unknown | Phase 1 / Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT06111625 | Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL | unknown | Phase 2 | 20 | Sichuan UniversityOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT05959694 | A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . | unknown | Phase 1 / Phase 2 | 107 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04754035 | Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia(IMPROVE) | unknown | Phase 2 | 31 | Paolo GhiaOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT02229422 | A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)(GA101 & HDMP) | unknown | Phase 1 / Phase 2 | 40 | University of California, San DiegoOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT02825836 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | unknown | Phase 1 / Phase 2 | 130 | Telios Pharma, Inc.INDUSTRY | 7 | Jul 13, 2023 | clinicaltrials |
| NCT05941156 | Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05932173 | A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 60 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04923048 | A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. | unknown | Phase 1 / Phase 2 | 460 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 22, 2023 | clinicaltrials |
| NCT05252403 | Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL | unknown | Phase 2 | 35 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05809167 | Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT | unknown | Phase 2 | 55 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT01593488 | Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children(CILI) | unknown | Phase 2 | 31 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05429905 | Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia | unknown | Phase 1 / Phase 2 | 48 | KK Women's and Children's HospitalOTHER_GOV | 1 | Mar 9, 2023 | clinicaltrials |
| NCT03467256 | CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | unknown | Phase 1 / Phase 2 | 18 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05381662 | CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment | unknown | Phase 1 / Phase 2 | 10 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Feb 10, 2023 | clinicaltrials |
| NCT02047578 | Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL. | unknown | Phase 2 | 38 | Seoul National University HospitalOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05639179 | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05291390 | Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 200 | Armaceutica, Inc.INDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT03460522 | Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL | unknown | Phase 2 | 65 | Nicola GoekbugetOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05578378 | Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL | unknown | Phase 2 / Phase 3 | 32 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05559450 | Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL | unknown | Phase 2 | 80 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT03280160 | Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab | unknown | Phase 2 | 84 | PETHEMA FoundationOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT05466175 | A Study of Olverembatinib in the Treatment of Ph+ ALL | unknown | Phase 2 | 55 | Chen SuningOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT03226301 | A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations | unknown | Phase 2 | 230 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 6 | Aug 2, 2022 | clinicaltrials |
| NCT03564470 | Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL | unknown | Phase 2 / Phase 3 | 120 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05287984 | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL(ZFCR/ZBR) | unknown | Phase 2 | 63 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04764513 | Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT | unknown | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT02776605 | Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia(PONALFIL) | unknown | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05066958 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | unknown | Phase 1 / Phase 2 | 20 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT03887156 | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft(Predictor2) | unknown | Phase 2 / Phase 3 | 227 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Sep 28, 2021 | clinicaltrials |
| NCT05054465 | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL(ITALLI001) | unknown | Phase 1 / Phase 2 | 48 | Israeli Medical AssociationOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT04334993 | Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study | unknown | Phase 2 | 110 | Israeli Medical AssociationOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04747093 | Induced-T Cell Like NK Cells for B Cell Malignancies | unknown | Phase 1 / Phase 2 | 12 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04740203 | Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL | unknown | Phase 1 / Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03156101 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 24 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03265106 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 20 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04723901 | Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04688983 | Study in Adult Ph-positive ALL(EWALL-Ph-03) | unknown | Phase 2 | 180 | Cardiff UniversityOTHER | 0 | Dec 30, 2020 | clinicaltrials |
| NCT02772198 | T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 300 | Sheba Medical CenterOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04534634 | Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL） | unknown | Phase 2 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT04453345 | TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL | unknown | Phase 2 / Phase 3 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04206943 | Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL(ISIKOK-19) | unknown | Phase 1 / Phase 2 | 24 | Acibadem UniversityOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT02605460 | Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission | unknown | Phase 2 | 20 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Jan 14, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jul 30, 2024source: clinicaltrials